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Background: Isovolemic anemia (decrease in hemoglobin concentration with normal or even increased blood
volume) after gastric cancer surgery may negatively influence short- and long-term outcomes. Therefore correction
of isovolemic postoperative anemia is supposed to be beneficial. This prospective randomized placebo-controlled
multicenter trial is designed to evaluate the efficacy of ferric carboxymaltose administration with the primary end
point of successful hemoglobin level increase by 2 g/dl at 12 weeks after randomization.
Methods and design: Gastric cancer patients after oncologic resection and postoperative hemoglobin level ≥ 7 g/dl
to <10 g/dl at postoperative days 5 to 7 will be eligible for trial inclusion. After randomization, 450 patients (225 per
group) are going to be subjected either to administration of ferric carboxymaltose (treatment group) or normal (0.9%)
saline (placebo group). Patients will be blinded to the intervention. Patients will undergo evaluation for hemoglobin
level, hematology and quality of life assessment 3 and 12 weeks after randomization.
Discussion: Correction of isovolemic postoperative anemia in gastric cancer patients after oncologic resection is
considered to be beneficial. Administration of ferric carboxymaltose is considered to be superior to placebo for anemia
correction without the possible risks of red blood cell transfusion. Further, improved quality of life for patients with
quick recovery of hemoglobin levels is expected.
Trial registration: NCT01725789 (international: www.clinicaltrials.gov) and NCCCTS-12-644 (NCC, Korea).
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Perioperative anemia occurs in 25% to 75% of cancer pa-
tients, and the prevalence of anemia in the immediate
postoperative period after major surgery is as high
as 90% [1,2]. Postoperative acute isovolemic anemia
(decrease in hemoglobin concentration with normal or
even increased blood volume) can affect the recovery
and quality of life (QoL) of patients by subtly slowing
the reaction time, deteriorating memory, increasing
heart rate, and decreasing oxygen levels [3,4]. It has been
suggested that low hemoglobin levels may affect onco-
logic outcomes in gastric cancer patients [5,6]. Jung
et al. revealed that low hemoglobin levels were related to
postoperative complications [5]. Further, it was demon-
strated that postoperative anemia resulted in decreased
overall survival [6]. Therefore correction of postopera-
tive anemia is an important issue. However, transfusion
guidelines and patient blood management programs are
not commonly implemented so far. This is reflected by
the fact that postoperative transfusion rates for colorec-
tal and gastric cancer patients were reported to be 10%
to 38% [7,8]. It was demonstrated before that transfusion
of red blood cells (RBC) carries substantial risks for pa-
tients and may even worsen postoperative oncologic
longterm outcome [9,10]. Those risks may be acute
hemolytic reactions, transfusion-related acute lung in-
jury, immunization events, organ dysfunctions, and fail-
ures and the possibility of incorrect transfusions. The
best evidence so far is derived from a meta-analysis for
red blood cell transfusions in colorectal cancer patients
which concludes that RBC transfusion is related to
higher cancer recurrence and decreased survival rates
[11]. This data was also confirmed for other tumor
entities such as pancreatic cancer and hepatocellular car-
cinoma [12,13]. Therefore alternative procedures to clas-
sical RBC-transfusion should be considered of highest
interest. Iron supplementation may be a conceivable
alternative. However, oral iron intake was reported to be
related to a considerable amount of side effects [14]
which can be hypersensitivity, paresthesia, hypotension,
dyspepsia, vomiting, abdominal pain, myalgia/arthralgia,
and pyrexia. Further, dietarian supplementation may
be hampered by substantially affected resorption from
the GI-tract after gastric cancer surgery [14]. Therefore
intravenous iron supplementation is a substantial alter-
native. However, iron dextran infusion is considered
to be rarely related to potentially life-threatening side
effects [15]. Alternatively ferric carboxymaltose was
proposed to be safer regarding the common side effects
of intravenous (iv-) iron infusion [15].
In a retrospective observational study performed at the
sponsor site the role of intravenous iron was assessed
before [16]. Postgastrectomy patients treated with iron
sucrose had a faster and more complete Hb-responsecompared to untreated patients and none of the treated
patients developed chronic anemia 12 months after sur-
gery. Further, no adverse events related to iron infusion
were noted. However, selection bias could not be ruled
out in this study, because in this retrospective analysis
the percentage of advanced gastric cancer patients
treated by intravenous iron was higher than in the non-
treated group. Therefore we propose this randomized
placebo controlled phase III trial in order to evaluate the
efficacy and safety of intravenous ferric carboxymaltose
supplementation for correction of postoperative isovole-
mic anemia in gastric cancer patients.
Methods
Study population, inclusion, and exclusion criteria
All patients with a hemoglobin-level ≥ 7 g/dl to <10 g/dl
at postoperative days 5 to 7 after oncologic gastrectomy
for gastric cancer will be eligible for screening. All pa-
tients aged 20 years and over and willing to give in-
formed consent will be eligible. Participation in another
trial interfering with the outcome of this study, language
problems, lack of compliance, mental inability, unstable
angina or myocardial infarction within 6 months of the
trial, severe respiratory disease, ASA (American Society
of Anesthesiologists) Score >3, inadequate liver, kidney,
and bone-marrow functions (evaluated by measurement
of white blood cell count (WBC), platelets, aspartate
aminotransferase (AST), alanine aminotransferase (ALT),
C-reactive protein (CRP), and creatinine), pregnancy/lac-
tation, and Eastern Cooperative Oncology Group (ECOG)
status >1 will be considered unspecific exclusion criteria.
Further, patients with a known history of hypersensitivity
or allergy to ferric carboxymaltose, active inflammatory
disease (surgical, site infection, pneumonia, Systemic
Inflammatory Response Syndrome (SIRS)), history of
previous erythropoietin or iv-iron administration within
4 weeks prior to screening, history of iron overload
(hemochromatosis) and anemia due to reasons other than
iron deficiency will not be eligible for this trial. The study
protocol was approved by the Institutional Review Board
(IRB) of the National Cancer Center Korea on 7 November
2012 (NCCCTS-12-644). All participating centers ap-
proved the trial by their local IRBs subsequently. Further,




After consenting to participate in the trial, patients
will be randomized to either one of the two treat-
ment groups (500 to 1,000 mg ferric carboxymaltose
(Ferinject®) vs. placebo (0.9% saline)). After inclusion of
eligible patients medical history will be taken and all
concomitant diseases and medications will be recorded.
Figure 1 Study scheme of FAIRY trial, inclusion/exclusion criteria, intervention, and end points.
Reim et al. Trials 2014, 15:111 Page 3 of 6
http://www.trialsjournal.com/content/15/1/111All trial participants will receive routine examination
and blood testing for the following parameters: hemog-
lobin, RBC, WBC, platelets, serum ferritin, transferrin
saturation, AST, ALT, CRP, and creatinine.
Assessment of quality of life
Quality of life (QoL) as one of the most important
secondary endpoints will be assessed by standardized
European Organization for Research and Treatment of
Cancer (EORTC) QLQ C-30, and STO-22 (EORTC
Study Group on Quality of Life) questionnaires, which
are already broadly established and validated. Crawford
and Cella [17] reported that the maximal incremental
gain in QoL occurs when the hemoglobin level lies inthe range of 11 to 13 g/dL. Differences in QoL were
even noted when the Hb-level was only 1 g/dL lower.
Therefore we hypothesize that rapid Hb-nomalization by
intravenous iron administration may improve QoL. As
such, QoL will be assessed at multiple time points post-
surgery during the follow-up visits.
Intervention
The treatment group will be administered ferric carboxy-
maltose (1,000 mg for bodyweight ≥50 kg or 500 mg for
bodyweight <50 kg (maximum dose of ferric carboxymal-
tose: 20 mg/kg)) as iv-drip infusion over an administration
time of at least 15 (1,000 mg) or 6 (500 mg) min. All
patients with a serum ferritin level of <15 ng/mL and
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ond administration of 500 mg ferric carboxymaltose as de-
scribed above. The placebo group will receive normal saline
(0.9%) as iv-drip infusion (200 mL for bodyweight ≥50 kg
or 100 mL for bodyweight <50 kg) over an administration
time of at least 15 (200 mL) or 6 (100 mL) min. During in-
fusion patients will be blinded.
Follow-up
Follow-up visits will take place at 3 and 12 weeks
(±7 days) after the study intervention. On the follow-up
visits patients will undergo blood testing and QoL evalu-
ation as described above.
Study objectives
Primary endpoint
The primary efficacy endpoint will be the number of re-
sponders defined as an increase of the hemoglobin level
of at least 2 g/dl related to the baseline hemoglobin
measured after randomization at 12 weeks after adminis-
tration of either placebo or ferric carboxymaltose.
Secondary endpoints
Major secondary endpoints will be: percentage of pa-
tients with Hb ≥10, 11, and 12 g/dL at 3 and 12 weeks
(independent of alternative anemia management includ-
ing transfusion or use of erythropoietin stimulating
agents), percentage of patients requiring alternative
anemia management therapy, average time-to-response
(Hb increase ≥2 g/dL and/or Hb ≥10 g/dL) (independent
of alternative anemia management including transfusion
or use of erythropoietin stimulating agent, development
of Hb, ferritin, and transferrin saturation over the study
duration (12 weeks) independent of alternative anemia
management including transfusion or use of erythropoi-
etin stimulating agents and finally safety/tolerability of
ferric carboxymaltose. QoL as one of the most important
secondary endpoints will be assessed by EORTC QLQ
C-30 and STO-22 questionnaires at 3 and 12 weeks.
Methods against bias
Randomization into two treatment groups will be per-
formed in order to omit selection bias from this trial.
Randomization will be performed as block randomiza-
tion in fixed block sizes in a 1:1 allocation ratio using
a centralized web-based randomization system (eVelos
(http://eresearch.ncc.re.kr/eres/jsp/ereslogin.jsp)). In order
to achieve equal group sizes randomization will be stratified
for each respective center (six centers). Further, patients will
be stratified according to the need of adjuvant chemother-
apy depending on the surgical/pathological stage (adjuvant
CTx in patients with clinical/surgical/pathological stages II
to IV according to UICC/AJCC [18]). Patient blinding will
rule out possible influences on QoL assessment. Patientsand observers for postoperative outcomes will be blinded
to guarantee an optimal study outcome. Potential con-
founding will be reduced by the randomization process.
Sample size calculation, statistical considerations, and
trial feasibility
The sample size is based on a superiority design assum-
ing a response rate to ferric carboxymaltose of 75%
(per primary endpoint definition) by week 12. A re-
sponse rate of 60% is assumed in the control group. This
results in a 15% advantage for the treatment group
which is considered medically meaningful. In order to
achieve a statistically significant result with 90% power
at a significance level of α = 0.05, 400 patients are re-
quired to be randomized according to the Pocock
formula [19]:
n ¼ f α; βð Þ  p1 100−p1ð Þ þ p2 100−p2ð Þ½ = p2−p1ð Þ2
where p1 and p2 are the response rates in the control
and experimental groups, respectively, and f(α, β) = [Φ− 1
(α/2) +Φ− 1(β)]2.
To account for potential patient drop-outs over the
12-week study period, the sample size is estimated at
450 patients (225 per group). Although this number
appears to be rather high, recruitment should be accom-
plished within several months. Each of the six participat-
ing centers treats at least 500 patients for gastric cancer
every year which sums up to a volume of 3,000 patients
per year. Based on the assumption of an incidence rate
of 15% for postoperative anemia (18% in the sponsor’s
institution) 400 patients may be recruited within one
year.
The outcome parameters will be analyzed by a Pearson
chi-square test or Fisher’s exact test (patient age and
gender, clinicopathologic data, and morbidity) and Stu-
dent’s t-test (Hb-level before treatment and hospital days
after treatment). The Z-test will be used to determine
whether or not a significant difference exists between
two groups during follow-up.
Safety
Stopping rules of the study medication will not apply
due to a single administration of ferric carboxymaltose.
However, in case of hypersensitivity or anaphylactic
reactions immediate interruption of infusion will be
mandatory. Further management will be left to the dis-
cretion of the physician on duty. Any (serious) adverse
event ((S) AE), any (unexpected) (serious) adverse drug
reaction, and any suspected unexpected serious adverse
reaction (SUSAR) will be documented. All SAEs, SADs,
and SUSARs will have to be documented and reported
to the IRB by the responsible investigator according to
local regulations.
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All information required by the study protocol and col-
lected during this trial will be entered in the electronic
case report form (eCRF) using the web-based eVelos sys-
tem (http://eresearch.ncc.re.kr/eres/jsp/ereslogin.jsp). The
completed eCRFs will be reviewed and signed by the in-
vestigator or subinvestigator and sent to the independent
data management group in the eVelos team. Quality con-
trol is going to be enforced by site visits and CRF review.
The data will be handled, managed, and analyzed accord-
ing to appropriate regional standard operating procedures.
The study will be conducted in accordance with ICH-
GCP and the Declaration of Helsinki.
Discussion
Postoperative anemia occurs in around 18% of patients
after oncologic gastrectomy [16]. This signifies a consid-
erable amount of patients in need of hemoglobin cor-
rection and prevention of chronic anemia. For gastric
cancer patients high level evidence derived from pro-
spective studies on anemia correction other than RBC
transfusion are not available yet. Therefore we propose
this prospective randomized placebo controlled trial.
Primary efficacy endpoint of this prospective study is
the number of treatment responders after administration
of either placebo or ferric carboxymaltose. Response is
defined as an increase of the hemoglobin level of at least
2 g/dl related to the baseline hemoglobin 12 weeks after
randomization. A hemoglobin level of 10 g/dl will be
used as a cutoff value for our study based on the guide-
lines published by the American Society of Clinical On-
cology and the American Society of Hematology for the
treatment of cancer-related anemia, recommending
Hb <10 g/dl as a treatment threshold [20]. The increase of
2 g/dl was chosen on the basis of the former FERGIcor
trial [21], which defined treatment responders to ferric
carboxymaltose when the hemoglobin level increased by
2 g/dl 12 weeks after initiation of treatment and revealed
significant improvements in QoL.
After gastrectomy, damage on the gut may impact the
ability of the patient to absorb iron from diet, limiting
correction of iron deficiency anemia [22]. Therefore an
intravenous compound was chosen for this trial. To
date, over 3,600 subjects were treated by ferric carboxy-
maltose in various clinical studies. Across those clinical
studies [14,15,21,23], replenishment of iron stores was
consistently observed. In subjects with more severe or
prolonged iron deficiency, anemia correction using ferric
corboxymaltose consistently resulted in medically sig-
nificant increases of Hb values. This improvement was
usually found within 2 weeks. In addition to the correc-
tion of laboratory parameters, iron replacement therapy
demonstrated significant improvements of QoL and
functional status. In phase III studies, ferric carboxymaltose(Ferinject®) was reported to have improved tolerability and
fewer side effects than iron sucrose [24] together with faster
correction of postoperative anemia.
Postoperative anemia may increase tumor resistance to
possibly necessary adjuvant chemotherapy in advanced
gastric cancer patients. It was found that anemia is the
strongest prognostic factor for oncologic outcomes of
5-fluorouracil-based chemotherapy [25]. Anemic pa-
tients revealed significantly lower response rates and
overall survival rates than those with regular Hb-levels.
Therefore it is of utmost interest to improve Hb-levels
for postoperative AGC patients who are supposed to
undergo adjuvant chemotherapy in a curative setting.
Besides that, baseline Hb may be lower for advanced
gastric cancer patients due to a higher risk of blood loss
due to more invasive surgery (open procedure, more ag-
gressive lymph node dissection, and longer operating
time) compared to early gastric cancer patients. As the
improvements on QoL may be more pronounced in this
group, AGC patients will have to be stratified in a sub-
group analysis.
Conclusively there is emerging evidence that patient
blood management for postoperative isovolemic anemia
may be superior to just observation or red blood cell
transfusion. The proposed study represents a well pow-
ered randomized placebo-controlled trial in order to elu-
cidate the influence of ferric carboxymaltose substitution
on correction of isovolemic anemia and QoL in gastric
cancer patients.
Trial status
Recruiting. The first patient was randomized in January
2013.
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